Cite
HARVARD Citation
Shitara, K. et al. (n.d.). 175POverall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). Annals of oncology. p. . [Online].